WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced its selection as one of the most innovative organizations using information technology at IDG’s CIO magazine’s 29th annual CIO 100 Awards.
PPD’s technology features innovations, including utilizing wearable or mHealth technology, and Preclarus®, PPD’s portfolio of solutions that provides clients transparent, real-time access to clinical trial operations and patient data to bring life-saving therapies to patients.
“The CIO 100 Award acknowledges PPD’s strategic technological solutions that enhance our clients’ ability to conduct clinical trials and help them deliver life-changing therapies to patients,” said Mike Wilkinson, executive vice president and chief information officer of PPD. “Our forward-looking technologies help to progress the management of real-time data and analytics to improve the way clinical teams perform their jobs.”
Recipients of the CIO 100 Award were selected by a panel of independent judges and CIO editors. CIO is published by IDG Enterprise, a subsidiary of International Data Group.
PPD accepted the award at the CIO Symposium and Awards Ceremony Aug. 16 in Rancho Palos Verdes, California, and was featured in the Aug. 1 issue of CIO magazine.
About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 17,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s award-winning technology solutions contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.
